Development of Liposomal Ciprofloxacin to Treat Lung Infections
AbstractExcept for management of Pseudomonas aeruginosa (PA) in cystic fibrosis, there are no approved inhaled antibiotic treatments for any other diseases or for infections from other pathogenic microorganisms such as tuberculosis, non-tuberculous mycobacteria, fungal infections or potential inhaled biowarfare agents including Francisella tularensis, Yersinia pestis and Coxiella burnetii (which cause pneumonic tularemia, plague and Q fever, respectively). Delivery of an antibiotic formulation via the inhalation route has the potential to provide high concentrations at the site of infection with reduced systemic exposure to limit side effects. A liposomal formulation may improve tolerability, increase compliance by reducing the dosing frequency, and enhance penetration of biofilms and treatment of intracellular infections. Two liposomal ciprofloxacin formulations (Lipoquin® and Pulmaquin®) that are in development by Aradigm Corporation are described here. View Full-Text
- Supplementary File 1:
PDF-Document (PDF, 743 KB)
Share & Cite This Article
Cipolla, D.; Blanchard, J.; Gonda, I. Development of Liposomal Ciprofloxacin to Treat Lung Infections. Pharmaceutics 2016, 8, 6.
Cipolla D, Blanchard J, Gonda I. Development of Liposomal Ciprofloxacin to Treat Lung Infections. Pharmaceutics. 2016; 8(1):6.Chicago/Turabian Style
Cipolla, David; Blanchard, Jim; Gonda, Igor. 2016. "Development of Liposomal Ciprofloxacin to Treat Lung Infections." Pharmaceutics 8, no. 1: 6.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.